Project Description

Results:
A Total of 99,362 patients were included and divided into five loop-diuretic dose groups: – 30,838 (31%) used no loop diuretics – 24,389 (25%) used >0-40 mg/day – 17,355 (17%) used >40-80 mg/day – 11,973 (12%) used >80- 159 mg/day – 14,807 (15%) used ≥160 mg/day A total of 7,958 patients (8%) developed diabetes Loop-diuretic dosages were associated with an increased risk of developing diabetes in a dose-dependent manner Concomitant use of Renin-angiotensin System inhibitors (RASis) attenuated the risk (p value for interaction <0.0001) Compared with patients using no loop diuretics (group 1), the adjusted HRs (95% CI) for developing diabetes for groups 2-5 respectively were - 1.16 (1.07, 1.26), 1.35 (1.24, 1.46), 1.48 (1.35, 1.62) and 1.76 (1.61, 1.92) with RASi treatment - 2.06 (1.83, 2.32), 2.28 (2.01, 2.59), 2.88 (2.52, 3.30) and 3.02 (2.66, 3.43) without RASi treatment Conclusion : In a nationwide cohort of patients with heart failure, severity of heart failure was associated with a stepwise increased risk of developing diabetes. Increased awareness of risk of diabetes associated with severe heart failure is warranted. Explanation: Heart failure leads to complications of Diabetes